<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210716</url>
  </required_header>
  <id_info>
    <org_study_id>FCRP- 0210</org_study_id>
    <nct_id>NCT01210716</nct_id>
  </id_info>
  <brief_title>Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device</brief_title>
  <official_title>Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fenwal, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fenwal, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the use of the AMICUS device in patients where Therapeutic Plasma
      Exchange (TPE) is prescribed by their physicians.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Therapeutic plasma exchange (TPE) is intended for efficient removal of circulating plasma,
      with the return of replacement fluids to the patient. In the majority of cases, the treatment
      goal is to selectively remove the substance directly responsible for the patient's disease
      process.

      Fenwal's AMICUS separator platform is a centrifuge-based apheresis system which collects the
      blood components of interest and returns the remaining blood components along with saline
      back to a donor/patient. The device has been cleared for the following:

        -  The collection of platelets and plasma in Japan, Europe and the US (BK960005), 1996.

        -  The collection of mononuclear cells (MNCs) in the US (BK000047), 2002.

        -  The collection of a concurrent red blood cell (cRBC) product collected in ACD-A
           anticoagulant and stored in ADSOLÂ® Preservation Solution (BK000039), 2002.

      Fenwal has developed a new protocol on the AMICUS separator that enables the device to
      perform TPE procedures. The procedure is similar to the FDA cleared platelet and concurrent
      plasma collections, except that in TPE procedures the majority of plasma is retained and the
      red blood cells (RBCs), white blood cells (WBC) and the majority of the platelets are
      returned to the patient.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Efficiency of Plasma Removal During the Therapeutic Plasma Exchange Procedure</measure>
    <time_frame>After completion of the TPE procedure.</time_frame>
    <description>The calculation is based on the volume of plasma that was processed through the machine compared to the volume of patient plasma that was actually removed during the procedure.
Plasma Efficiency = (plasma removed/plasma processed)*100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Measured by Adverse Events During the TPE Procedure</measure>
    <time_frame>Adverse events were collected during each TPE procedure.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Autoimmune Diseases</condition>
  <condition>Renal Disorders</condition>
  <condition>Hematologic Disorders</condition>
  <condition>Oncologic Disorders</condition>
  <arm_group>
    <arm_group_label>AMICUS Therapeutic plasma exchange, TPE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are randomized to either TPE on AMICUS or Spectra.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spectra Therapeutic plasma exchange, TPE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients are randomized to either TPE on AMICUS or Spectra.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Therapeutic plasma exchange</intervention_name>
    <description>Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.</description>
    <arm_group_label>AMICUS Therapeutic plasma exchange, TPE</arm_group_label>
    <arm_group_label>Spectra Therapeutic plasma exchange, TPE</arm_group_label>
    <other_name>TPE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Medically stable patients undergoing more than one TPE procedure who have provided
             signed informed consent prior to participation.

          2. A physician's prescription for TPE for various non-emergent conditions.

          3. Test and Control TPE procedures that would be expected to be completed within
             approximately five weeks.

        Exclusion Criteria:

          1. Patients under 18 years old.

          2. Patients on an ACE inhibitor medication should discontinue use of this medication in
             accordance with institutional practices.

          3. Patients with altered mental status that would prohibit the giving and understanding
             of informed consent.

          4. Patients who have experienced a serious adverse event associated with the first TPE
             clinical study procedure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peyton Metzel, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fenwal, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BloodCenter of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2010</study_first_submitted>
  <study_first_submitted_qc>September 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2010</study_first_posted>
  <results_first_submitted>March 13, 2012</results_first_submitted>
  <results_first_submitted_qc>September 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 23, 2013</results_first_posted>
  <last_update_submitted>September 20, 2013</last_update_submitted>
  <last_update_submitted_qc>September 20, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic plasma exchange</keyword>
  <keyword>Autoimmune diseases</keyword>
  <keyword>Kidney transplant</keyword>
  <keyword>Hematologic disorders</keyword>
  <keyword>Monoclonal gammopathy</keyword>
  <keyword>Neurologic disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Autoimmune Diseases</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study opened enrollment on Sept 2010 at three hospitals-Yale New Haven Hospital, Mayo Clinic and University of Virginia Health System. A 4th site, BloodCenter of Wisconsin opened enrollment April,2011.</recruitment_details>
      <pre_assignment_details>Patients were required to complete two (2) procedures. First procedure was randomized to either Therapeutic plasma exchange on active comparator (AMICUS) or current device (Spectra). The second procedure was completed within approximately 5 weeks on the other device per physician prescription.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Spectra First, Then AMICUS</title>
          <description>Patients randomized to Control (Spectra) procedure first. Second procedure performed was Test (AMICUS).</description>
        </group>
        <group group_id="P2">
          <title>AMICUS First, Then Spectra</title>
          <description>Patients randomized to Test (AMICUS) procedure first. Second procedure performed was Control (Spectra).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First TPE Procedure</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second TPE Procedure</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demographics were reported for the evaluable patient population.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study Population</title>
          <description>Includes groups randomized to receive Spectra first and AMICUS first.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.7" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Efficiency of Plasma Removal During the Therapeutic Plasma Exchange Procedure</title>
        <description>The calculation is based on the volume of plasma that was processed through the machine compared to the volume of patient plasma that was actually removed during the procedure.
Plasma Efficiency = (plasma removed/plasma processed)*100</description>
        <time_frame>After completion of the TPE procedure.</time_frame>
        <population>A total of 37 patients who consented and enrolled started the 1st procedure. Of these 37 patients, 33 patients completed the 1st procedure and started a 2nd procedure. Three patients did not complete the second procedure resulting in 30 patients with completed paired Test and Control procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>AMICUS (Test)</title>
            <description>Each evaluable patient underwent one complete TPE procedure on the AMICUS separator.</description>
          </group>
          <group group_id="O2">
            <title>Spectra (Control)</title>
            <description>Each evaluable patient underwent one complete TPE procedure on the COBE Spectra separator.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Efficiency of Plasma Removal During the Therapeutic Plasma Exchange Procedure</title>
          <description>The calculation is based on the volume of plasma that was processed through the machine compared to the volume of patient plasma that was actually removed during the procedure.
Plasma Efficiency = (plasma removed/plasma processed)*100</description>
          <population>A total of 37 patients who consented and enrolled started the 1st procedure. Of these 37 patients, 33 patients completed the 1st procedure and started a 2nd procedure. Three patients did not complete the second procedure resulting in 30 patients with completed paired Test and Control procedures.</population>
          <units>percentage of plasma removal efficiency</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.9" lower_limit="68" upper_limit="96"/>
                    <measurement group_id="O2" value="75.2" lower_limit="61" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>A one-sample t-test on the mean of paired differences was used to evaluate the primary objective. Sample size was determined using historical data and the 95% chi-square upper confidence limit on the observed standard deviation of the paired differences. A minimum sample of 27 pairs was required to demonstrate the AMICUS procedure to be non-inferior to Spectra with a mean efficiency of plasma removal with a non-inferiority margin of 15% with at least 97.5% (one-sided) confidence and 90% power.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>If the lower 97.5% confidence limit on the mean of the paired differences is greater than -15% of the Control group mean (i.e., p-value &lt;=0.05), then the Test group will be considered non-inferior in the primary efficacy parameter to Control at the margin of 15%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>paired t-test</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.69</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>6.970</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>4.0</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety Measured by Adverse Events During the TPE Procedure</title>
        <time_frame>Adverse events were collected during each TPE procedure.</time_frame>
        <population>Adverse events were summarized for enrolled subjects per protocol. 7 out of 37 enrolled subjects experienced adverse events during the study with a total of 12 adverse events reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Overall Study Population</title>
            <description>Includes groups randomized to receive Spectra first and AMICUS first.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety Measured by Adverse Events During the TPE Procedure</title>
          <population>Adverse events were summarized for enrolled subjects per protocol. 7 out of 37 enrolled subjects experienced adverse events during the study with a total of 12 adverse events reported.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="61" upper_limit="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Overall Study Population</title>
          <description>Includes groups randomized to receive Spectra first and AMICUS first.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rigors</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizzy/Light-Headed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Infiltration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Publication of data and/or information derived from the study requires prior review and approval by Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sr. Mgr. Clinical Affairs</name_or_title>
      <organization>Fenwal, Inc</organization>
      <phone>847-550-5620</phone>
      <email>carrie.pineda@fenwalinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

